Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel

The aim of this study was to evaluate the impact of certain single-nucleotide polymorphisms (SNPs) in cabazitaxel activity and toxicity in patients with metastatic castration-resistant prostate cancer (mCRPC). 56 SNPs in five genes ( , , , and ) were genotyped in 67 mCRPC patients and their correlation with outcomes analyzed. -rs151352 (hazard ratio: 0.52) and -rs1341164 (hazard ratio: 0.53) were associated with better overall survival, and -rs1058932 with biochemical progression (odds ratio: 6.60) in multivariate analysis. -rs17327624 correlated with severe toxicity ≥grade 3 (odds ratio: 8.56) and -rs11572093 with asthenia (odds ratio: 8.12). Genetic variants in mCRPC patients could explain different outcomes with cabazitaxel. Nonetheless, the small sample size and the high number of SNPs analyzed mean that the results are only hypothesis-generating and require further validation.